Rituximab: a novel treatment for refractory Riedel's thyroiditis

Area of Science:

• Endocrinology
• Immunology

Background:

• Riedel's thyroiditis is a rare, benign condition characterized by chronic inflammation and extensive fibrosis of the thyroid gland.
• It can present with compressive symptoms like neck pain, dysphagia, and dyspnea, often mimicking malignancy.
• Riedel's thyroiditis is increasingly recognized as a manifestation of IgG4-related systemic disorders.

Purpose of the Study:

• To review the clinical presentation and management challenges of Riedel's thyroiditis.
• To highlight the use of rituximab as a novel therapeutic approach for this condition.
• To report on the efficacy of rituximab in achieving symptom resolution in a patient with Riedel's thyroiditis.

Main Methods:

• Case report detailing a patient with Riedel's thyroiditis.
• Review of management strategies, including patient symptoms, medication side effects, and disease relapses.
• Evaluation of rituximab treatment, a monoclonal antibody targeting CD20+ B cells.

Main Results:

• The case highlights the difficulties in managing Riedel's thyroiditis due to its relapsing nature and treatment side effects.
• Rituximab therapy demonstrated effectiveness in resolving the patient's symptoms.
• The mechanism of action of rituximab involves targeting CD20 on B cells, contributing to immune modulation.

Conclusions:

• Riedel's thyroiditis presents with thyroid fibrosis and can cause significant symptoms.
• Management requires addressing symptom control, medication adverse effects, and the potential for recurrence.
• Rituximab offers a promising novel treatment option for Riedel's thyroiditis, showing efficacy in symptom resolution.